Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 9, Issue 1, 2016, Pages 9-30

  Zettl, Uwe K ^a   Rommer, Paulus ^a   Hipp, Petra ^b   Patejdl, Robert ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Medical University ^*  (Germany)

Author keywords

cannabinoids; CBD; multiple sclerosis; nabiximols; spasticity; THC

Indexed keywords

BACLOFEN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; NABIXIMOLS; PLACEBO; TIZANIDINE; TOLPERISONE;

CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEMALE; GABAERGIC SYSTEM; GLUTAMATERGIC SYNAPSE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; ORAL SPRAY; OROMUCOSAL SPRAY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPASTICITY; SYMPTOMATOLOGY; VERTIGO; VISUAL ANALOG SCALE;

EID: 84951191416     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285615612659     Document Type: Review

References (104)

1. Anwar K. Barnes M. (2009) A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 24: 333–340.
2. Aragona M. Onesti E. Tomassini V. Conte A. Gupta S. Gilio F. et al. (2009) Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 32: 41–47.
3. Arroyo R. Vila C. Dechant K. (2013) Impact of Sativex® on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res 3: 435–444.
4. Arseneault L. Cannon M. Witton J. Murray R. (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184: 110–117.
5. Ashworth B. (1964) Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192: 540–542.
6. Baker D. Pryce G. Croxford J. Brown P. Pertwee R. Makriyannis A. et al. (2000) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15: 300–302.
7. Barnes M. Kent R. Semlyen J. McMullen K. (2003) Spasticity in multiple sclerosis. Neurorehabil Neural Repair 17: 66–70.
8. Beard S. Hunn A. Wight J. (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technology Assessment 7: 1–111.
9. Bisogno T. Hanus L. de Petrocellis L. Tchilibon S. Ponde D.E. Brandi I. et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR 1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Brit J Pharmacol 134: 845–852.
10. Bohannon R. Smith M. (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67: 206–207.
11. Browne P. Chandraratna D. Angood C. Tremlett H. Baker C. Taylor B. et al. (2014) Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83: 1022–1024.
12. Collin C. Davies P. Mutiboko I. Ratcliffe S. (2007) Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 14: 290–296.
13. Collin C. Ehler E. Waberzinek G. Alsindi Z. Davies P. Powell K. et al. (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32: 451–459.
14. Colver A. Fairhurst C. Pharoah P. (2014) Cerebral palsy. Lancet 383: 1240–1249.
15. Crayton H. Rossman H. (2006) Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther 28: 445–460.
16. Devos H. Brijs T. Alders G. Wets G. Feys P. (2013) Driving performance in persons with mild to moderate symptoms of multiple sclerosis. Disabil Rehabil 35: 1387–1393.
17. Di Marzo V. Petrosino S. (2007) Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18: 129–140.
18. Eltayb A. Etges T. Wright S. (2013) An observational post-approval registry study of patients prescribed Sativex®. Results from clinical practice. Mult Scler 19(Suppl.): P1041
19. Farrar J. Troxel A. Stott C. Duncombe P. Jensen M. (2008) Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 30: 974–985.
20. Fernández O. (2014) Advances in the management of MS spasticity: recent observational studies. Eur Neurol 72 (Suppl. 1): 12–14.
21. Flachenecker P. (2013) A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev Neurother 13(Suppl. 1): 15–19.
22. Flachenecker P. Stuke K. (2008) National MS registries. J Neurol 255: 102–108.
23. Flachenecker P. Henze T. Zettl U. (2014 a) Spasticity in patients with multiple sclerosis-clinical characteristics, treatment and quality of life. Acta Neurol Scand 129: 154–162.
24. Flachenecker P. Henze T. Zettl U. (2014 b) Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice - results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 71: 271–279.
25. Flachenecker P. Henze T. Zettl U. (2014 c) Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 72: 95–102.
26. Fleuren J. Voerman G. Erren-Wolters C. Snoek G. Rietman J. Hermens H. et al. (2010) Stop using the Ashworth Scale for the assessment of spasticity, J Neurol Neurosurg Psychiatry 81: 46–52.
27. Freidel M. Tiel-Wilck K. Schreiber H. Prechtl A. Essner U. Lang M. (2015) Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability. Acta Neurol Scand 131: 9–16.
28. Gaoni Y. Mechoulam R. (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646–1647.
29. García-Merino A. (2013) Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 13: 9–13.
30. Goldenberg M. (2012) Multiple sclerosis review. P T 37: 175–184.
31. Guy G. Robson P. (2003) A Phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK02125). J Cannabis Ther 3: 121–152.
32. Guy G. Stott C. (2005) The development of Sativex® – a natural cannabis-based medicine. In: Ed. Mechoulam R. (ed.), Cannabinoids as Therapeutics. Basel: Birkhäuser Verlag, pp. 231–263.
33. Henze T. Mackensen S. von Lehrieder G. Zettl U. Pfiffner C. Flachenecker P. (2014) Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany. Health Qual Life Outcomes 12: 119.
34. Henze T. Rieckmann P. Toyka K. (2006) Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 56: 78–105.
35. Hewitt D. Ho T. Galer B. Backonja M. Markovitz P. Gammaitoni A. et al. (2011) Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 152: 514–521.
36. Hilliard A. Stott C. Wright S. Guy G. Pryce G. Al-Izki, S.et al. (2012) Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis. ISRN Neurol, 2012: article ID 802649.
37. Hobart J. Riazi A. Thompson A. Styles I. Ingram W. Vickery P. et al. (2006) Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129: 224–234.
38. Hoffman A. Lupica C. (2000) Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20: 2470–2479.
39. International Association for the Study of Pain (2004) Unrelieved pain is a major global healthcare problem. Available at: http://www.iasp-pain.org/files/Content/ContentFolders/GlobalYearAgainstPain2/20042005RighttoPainRelief/factsheet.pdf (accessed 7 October 2015).
40. Izzo A. Borrelli F. Capasso R. Di Marzo V. Mechoulam R. (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515–527.
41. Johns A. (2001) Psychiatric effects of cannabis. Br J Psychiatry 178: 116–122.
42. Johnson J. Burnell-Nugent M. Lossignol D. Ganae-Motan E. Potts R. Fallon M. (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39: 167–179.
43. Johnson J. Lossignol D. Burnell-Nugent M. Fallon M. (2013) An open-label extension study to investigate the long-term safety and tolerability of THC / CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46: 207–218.
44. Kabus C. Hecht M. Japp G. Jost W. Pohlau D. Stuckrad-Barre S. et al. (2006) Botulinum toxin in patients with multiple sclerosis. J Neurol 25 (Suppl. 1): I26–I28
45. Kamin F. Rommer P. Abu-Mugheisib M. Koehler W. Hoffmann F. Winkelmann A. et al. (2014) Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity. Spinal Cord. DOI: 10.1038/sc.2014.155.
46. Karschner E. Darwin W. Goodwin R. Wright S. Huestis M. (2011) Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57: 66–75.
47. Killestein J. Polman C. (2004) The therapeutic value of cannabinoids in MS: real or imaginary? Mult Scler 10: 339–340.
48. Kister I. Bacon T. Chamot E. Salter A. Cutter G. Kalina J. Herbert J. (2013) Natural history of multiple sclerosis symptoms. Int J MS Care 15: 146–158.
49. Koehler J. Feneberg W. Meier M. Pollmann W. (2014) Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 124: 652–656.
50. Kutzelnigg A. Lassmann H. (2014) Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol 122: 15–58.
51. Leussink V. Husseini L. Warnke C. Broussalis E. Hartung H. Kieseier B. (2012) Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord 5: 255–266.
52. Marcotte T. Rosenthal T. Roberts E. Lampinen S. Scott J. Allen R. et al. (2008) The contribution of cognition and spasticity to driving performance in multiple sclerosis’. Arch Phys Med Rehabil 89: 1753–1758.
53. Moreno Torres I. Sanchez A.J. Garcia-Merino A. (2014) Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Rev Neurother 14: 1243–1250.
54. Notcutt W. Langford R. Davies P. Ratcliffe S. Potts R. (2012) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult Scler 18: 219–228.
55. Novotna A. Mares J. Ratcliffe S. Novakova I. Vachova M. Zapletalova O. et al. (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®) as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18: 1122–1131.
56. Oreja-Guevara C. Blasco R. Casanova B. Ordás C. Vila Silván C. Asensio D. et al. (2015) Observational safety study of THC / CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity. Clin Exp Pharmacol 5: 184. doi:10.4172/2161-1459.1000184.
57. Oreja-Guevara C. Gonzalez-Segra D. Vila C. (2013) Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 123: 400–408.4
58. Pachman D. Barton D. Swetz K. Loprinzi C. (2012) Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol 30: 3687–3696.
59. Penn R. Savoy S. Corcos D. Latash M. Gottlieb G. Parke B. et al. (1989) Intrathecal baclofen for severe spinal spasticity. New Engl J Med 320: 517–1521.
60. Perez J. (2006) Combined cannabinoid therapy via an oromucosal spray. Drugs Today 42: 495–503.
61. Perez J. Ribera M. (2008) Managing neuropathic pain with Sativex: a review of its pros and cons. Expert Opin Pharmacother 9: 1189–1195.
62. Pertwee R. (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635–664.
63. Pertwee R. (2000) Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol 5: 37–46.
64. Pertwee R. (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147(Suppl. 1): S163–S171.
65. Pertwee R. (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397–411.
66. Pinto P. Poretti A. Meoded A. Tekes A. Huisman T. (2012) The unique features of traumatic brain injury in children. Review of the characteristics of the pediatric skull and brain, mechanisms of trauma, patterns of injury, complications and their imaging findings – part 1. J Neuroimaging 22: e1–e17.
67. Platz T. Eickhof C. Nuyens G. Vuadens P. (2005) Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 27: 7–18.
68. Portenoy R. Ganae-Motan E. Allende S. Yanagihara R. Shaiova L. Weinstein S. et al. (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13: 438–449.
69. Pryce G. Baker D. (2007) Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 150: 519–525.
70. Rizzo M. Hadjimichael O. Preiningerova J. Vollmer T. (2004) Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10: 589–595.
71. Robson P. (2011) Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 10: 675–685.
72. Russo E. Guy G. (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234–246.
73. Russo M. Calabro R. Naro A. Sessa E. Rifici C. D'Aleo, G.et al. (2015) Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast 2015: article ID 656582.
74. Sastre-Garriga J. Vila C. Clissold S. Montalban X. (2011) THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 11: 627–637.
75. Schoedel K. Chen N. Hilliard A. White L. Stott C. Russo E. et al. (2011) A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 26: 224–236.
76. Schuhfried GmbH (2012) Wiener test system, Manual FEV. Anlage 5 Nr. 2. Mödling, Austria: Schuhfried GmbH.
77. Serpell M. Notcutt W. Collin C. (2013) Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 260: 285–295.
78. Serpell M. Ratcliffe S. Hovorka J. Schofield M. Taylor L. Lauder H. et al. (2014) A double-blind, randomized, placebo-controlled, parallel group study of THC / CBD spray in peripheral neuropathic pain treatment. Eur J Pain 18: 999–1012.
79. Shakespeare D. Boggild M. Young C. (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 4: CD001332.
80. Showalter V.M. Compton D.R. Martin B.R. Abood M.E. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989–999.
81. Slof J. Gras A. (2012) Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res 12: 439–441.
82. Slof J. Ruiz L. Vila C. (2015) Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. Expert Rev Pharmacoecon Outcomes Res 16: 1–13.
83. Smyth M. Peacock W. (2000) The surgical treatment of spasticity. Muscle Nerve 23: 153–163.
84. Solowij N. Stephens R. Roffman R. Babor T. Kadden R. Miller M. et al. (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287: 1123–1131.
85. Stevenson V. (2010) Rehabilitation in practice: spasticity management. Clin Rehabil 24: 293–304.
86. Stott C. White L. Wright S. Wilbraham D. Guy G. (2013 a) A phase I study to assess the single and multiple dose pharmacokinetics of THC / CBD oromucosal spray. Eur J Clin Pharmacol 69: 1135–1147.
87. Stott C. White L. Wright S. Wilbraham D. Guy G. (2013 b) A phase I study to assess the effect of food on the single dose bioavailability of the THC / CBD oromucosal spray. Eur J Clin Pharmacol 69: 825–834.
88. Stott C. White L. Wright S. Wilbraham D. Guy G. (2013 c) A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC / CBD oromucosal spray in healthy volunteers. Springerplus 2: 236.
89. Stott C. Wright S. Guy G. (2008) Comparison of pharmacokinetic profiles of inhaled delta-9-tetra-hydro-cannabinol (THC) from smoked cannabis with Sativex oromucosal spray in humans, implications for possible symptomatic treatment in multiple sclerosis. Eur J Neurol 15(Suppl. 3): 365.
90. Sunnerhagen K. (2010) Stop using the Ashworth scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 81: 2.
91. Svensson J. Borg S. Nilsson P. (2014) Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 129: 13–20.
92. Syed Y. McKeage K. Scott L. (2014) Delta-9-tetrahydrocannabinol/ cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs 74: 563–578.
93. Vachová M. Novotná A. Mares J. Taláb R. Fiedler J. et al. (2014) A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis. J Mult Scler 1: 122. doi:10.4172/jmso.1000122
94. Vermersch P. (2014) MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. Neurodegener Dis Manag 4: 407–415.
95. Voerman G. Gregoric M. Hermens H. (2005) Neurophysiological methods for the assessment of spasticity: the Hoffmann reflex, the tendon reflex, and the stretch reflex. Disabil Rehabil 27: 33–68.
96. von Linnaeus C. (1753) Species plantarum, Species plantarum 2. Stockholm: L. Salvius.
97. Wade D. Collin C. Stott C. Duncombe P. (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16: 707–714.
98. Wade D. Makela P. House H. Bateman C. Robson P. (2006) Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12: 639–645.
99. Wade D. Makela P. Robson P. House H. Bateman C. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients, Mult Scler 10: 434–441.
100. Ware M. Adams H. Guy G. (2005) The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 59: 291–295.
101. Wood D. Burridge J. van Wijck F. McFadden C. Hitchcock R. Pandyan A. et al. (2005) Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: a systematic review of the literature. Disabil Rehabil 27: 19–32.
102. Zettl U. Henze T. Essner U. Flachenecker P. (2013) Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (MOVE 1). Eur J Health Econ 15: 953–966.
103. Zettl U. Stüve O. Patejdl R. (2012) Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 11: 167–173.
104. Zwibel H. (2009) Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 26: 1043–1057.